HF
CORT icon

HRT Financial’s Corcept Therapeutics CORT Stock Holding History

HRT Financial’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
168,678
+95,825
+132% +$5.79M 0.03% 595
2026
Q1 		$2.94M Sell
72,853
-125,675
-63% -$4.7M 0.01% 1333
2025
Q4 		$6.91M Buy
+198,528
New +$15.6M 0.02% 621
2025
Q3 		– Sell
-200,996
Closed -$14.8M – 2965
2025
Q2 		$14.8M Buy
+200,996
New +$14.6M 0.06% 214
2025
Q1 		– Sell
-5,385
Closed -$271K – 2630
2024
Q4 		$271K Buy
+5,385
New +$282K ﹤0.01% 1772
2024
Q2 		– Sell
-20,890
Closed -$526K – 2340
2024
Q1 		$526K Sell
20,890
-38,944
-65% -$920K ﹤0.01% 1230
2023
Q4 		$1.94M Buy
59,834
+27,777
+87% +$763K 0.01% 662
2023
Q3 		$873K Sell
32,057
-76,185
-70% -$2.2M 0.01% 1075
2023
Q2 		$2.41M Buy
108,242
+97,741
+931% +$2.25M 0.02% 536
2023
Q1 		$227K Sell
10,501
-118,509
-92% -$2.6M ﹤0.01% 1866
2022
Q4 		$2.62M Buy
129,010
+119,319
+1,231% +$2.99M 0.04% 477
2022
Q3 		$248K Sell
9,691
-50,883
-84% -$1.36M ﹤0.01% 2112
2022
Q2 		$1.44M Sell
60,574
-42,934
-41% -$935K 0.02% 726
2022
Q1 		$2.33M Sell
103,508
-42,595
-29% -$906K 0.02% 574
2021
Q4 		$2.89M Buy
146,103
+90,461
+163% +$1.84M 0.02% 476
2021
Q3 		$1.09M Buy
55,642
+28,268
+103% +$592K 0.01% 1173
2021
Q2 		$602K Buy
27,374
+17,251
+170% +$384K 0.01% 1597
2021
Q1 		$240K Buy
+10,123
New +$270K ﹤0.01% 2218
2019
Q4 		– Sell
-21,650
Closed -$306K – 1217
2019
Q3 		$306K Buy
+21,650
New +$266K 0.01% 931

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRT Financial's CORT Position: Q2 2026 in Review

HRT Financial increased its Corcept Therapeutics (CORT) stake by 132% in Q2 2026, buying an estimated $5.79M and bringing the position to 168,678 shares worth $14.7M. The position accounts for 0.03% of the portfolio, ranked #595.

HRT Financial first reported a position in CORT in Q3 2019 and has held it in 19 quarters since. The position peaked at $14.8M in Q2 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • HRT Financial held 168,678 shares of Corcept Therapeutics worth $14.7M as of Q2 2026.
  • HRT Financial bought 95,825 Corcept Therapeutics shares in Q2 2026, an estimated $5.79M.
  • Corcept Therapeutics made up 0.03% of HRT Financial's portfolio in Q2 2026, its #595 holding.
  • HRT Financial first reported a position in Corcept Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • HRT Financial's Corcept Therapeutics position peaked at $14.8M in Q2 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.